HK Stock Market Move | CSPC PHARMA (01093) rose more than 4% as Chairman Cai Dongchen increased his holdings. SYH2085 tablets have been approved for clinical trials in China.

CSPC PHARMA (01093) rose more than 4%, as of the time of writing, it rose 4.12% to 8.59 Hong Kong dollars, with a turnover of 443 million Hong Kong dollars. On the news front, the latest data from the Hong Kong Stock Exchange shows that on December 22, Chairman and Executive Director Cai Dongchen increased his holdings of CSPC PHARMA by 134.54 million shares, priced at 8.1957 Hong Kong dollars per share, for a total amount of approximately 1.1 billion Hong Kong dollars. The latest number of holdings after the increase is approximately 2.91 billion shares, with a latest holding ratio of 25.26%. Recently, CSPC PHARMA announced that the SYH2085 tablets developed by the group have been approved by the National Medical Products Administration of the People's Republic of China for clinical trials in China. This product is a chemically innovative drug developed by the group on its own, and is a new oral small molecule candidate drug that can inhibit the RNA polymerase acid protein (PA) endonuclease activity of the influenza virus. The approved clinical indication for this time is for the treatment of adults and adolescents aged 12 and above with uncomplicated influenza A and B. This product is expected to become an effective drug for treating influenza, with high clinical development value, and will further enrich the group's product pipeline in the field of anti-infective treatment.